Table 1.
Demographics, task performance and clinical characteristics of participants
| Demographics | CBT for psychosis + TAU group (n = 22, 18 males) |
TAU-alone group (n = 16, 14 males) |
||
|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | |
| Baseline | Follow-up | Baseline | Follow-up | |
| Age (years) | 35.68 (7.82) | 39.19 (9.37) | ||
| Education (years) | 13.90 (3.26) | 13.56 (1.71) | ||
| Predicted IQa | 109.38 (9.68) | 106.64 (9.73) | ||
| Age at illness onset (years) | 24.77 (8.38) | 25.81 (8.49) | ||
| Duration of illness (years) | 10.91 (7.70) | 13.37 (10.16) | ||
| Performance | ||||
| Gender discrimination accuracy (%) | ||||
| Neutral | 92.62 (10.81) | 91.76 (13.14) | 88.28 (10.79) | 90.04 (14.57) |
| Fear | 90.48 (14.35) | 91.36 (16.53) | 87.89 (20.94) | 87.89 (18.46) |
| Anger | 88.63 (15.23) | 88.92 (14.16) | 84.77 (16.05) | 87.30 (19.07) |
| Happy | 94.74 (8.48) | 93.32 (9.94) | 92.38 (7.82) | 90.82 (12.31) |
| Detection (%) | ||||
| No face | 93.39 (12.39) | 91.48 (16.42) | 93.80 (13.72) | 92.48 (18.12) |
| PANSSb symptoms | ||||
| Positive symptoms | 18.09 (4.84) | 14.86* (4.10) | 18.56 (3.20) | 18.06 (3.30) |
| Negative symptoms | 17.73 (4.23) | 15.59* (4.29) | 19.13 (4.13) | 20.31 (4.38) |
| General psychopathology | 33.45 (7.24) | 28.59* (7.40) | 35.38 (4.41) | 35.38 (6.49) |
| Total symptoms | 69.27 (13.30) | 59.04* (14.73) | 73.06 (9.28) | 73.75 (11.83) |
| Antipsychotic medication | ||||
| Type | 20 patients on atypical; 2 on both atypical and typical antipsychotics | As baseline | 14 patients on atypical; 2 on both atypical and typical antipsychotics | As baseline |
| Dose in chlorpromazine equivalents (mg) | 543.00 (479.34) | 448.92 (338.84) | ||
Duration of illness = current age minus age of illness onset.
a National Adult Reading Test (Nelson and Willison, 1991).
*Symptom reduction (P < 0.05) in the CBT for psychosis + TAU, relative to the TAU alone group (no significant change in TAU-alone group, P > 0.05), at follow-up relative to baseline.